Skip to main content

Table 3 Baseline characteristic of the ELBW infants whose DA was closed after 2nd course COI vs. those whose DA remained patent after 2nd course

From: Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants

 

Closed (n = 42)

Not Closed (n = 37)

P

BW, gm

777 (17)

724 (21)

ns

GA, wks

25.5 (0.2)

24.9 (0.2)

0.007

Male Gender (%)

23 (55%)

15 (41%)

ns

CRIB II score

12.0 (0.3)

12.9 (0.4)

ns

OI

3.7 (0.3)

4.7 (0.5)

ns

Intubated > 2 days

36 (85.7%)

34 (91.9%)

ns

Age 1st Dose, days

5.6 (0.6)

7.3 (2.0)

ns